Literature DB >> 35074727

Global challenges and policy solutions in breast cancer control.

Dario Trapani1, Ophira Ginsburg2, Temidayo Fadelu3, Nancy U Lin3, Michael Hassett3, Andre M Ilbawi4, Benjamin O Anderson5, Giuseppe Curigliano6.   

Abstract

Breast cancer is the leading cause of cancer morbidity, disability and mortality in women, worldwide. Overall, in 2020, it was the most diagnosed malignancy. Differences in breast cancer mortality have been historically evidenced, as a result of disparities in access to diagnosis, treatment and palliative care. Epidemiologic trends in the last decades display three main patterns of breast cancer mortality: some high-income countries report continuous substantial improvements exceeding 2% annual mortality reduction; however, many low- and middle-income countries (LMICs) have stagnant or even increasing mortality rates. Population-based studies show that investing in breast cancer control, based on a primary health care approach, and expanding the cancer treatment capacity can portend population health benefits, with positive changes of the epidemiological adverse trajectories. Framed as part of the political commitment to the Sustainable Development Goals Agenda, World Health Organization (WHO) has recently launched a global initiative to tackle disparities in breast cancer mortality. The WHO-led Global Breast Cancer Initiative (GBCI) is framed across 3 pillars, to address key determinants of the cancer-related outcomes: health promotion and early detection, timely access to diagnosis and treatment, comprehensive breast cancer treatment, palliative and survivorship care. GBCI is a systematized approach, with the goal to (i) increase the fraction of newly diagnosed invasive cancers being stage 1 or 2 at diagnosis (60% or more), (ii) ensure diagnostic work-up to be completed within 60 days from the first connection with the primary healthcare providers to avoid delays in diagnosis and treatment and (iii) assure 80% or more women with breast cancer to undergo and complete multimodal treatments. GBCI will pursue a comprehensive and multisectoral approach, to deliver population health, social and economic benefits, ultimately intended as an entry point for health system strengthening and for the broader cancer control.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Cancer control; Cancer policy; Global breast cancer initiative; Global oncology; World Health Organization

Mesh:

Year:  2022        PMID: 35074727     DOI: 10.1016/j.ctrv.2022.102339

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  6 in total

1.  Prevalence of cancer in relation to signs of periodontal inflammation.

Authors:  Jukka H Meurman; Håkan Källmén; Leif C Andersson; Tulay Yucel-Lindberg; Birgitta Söder
Journal:  PLoS One       Date:  2022-10-21       Impact factor: 3.752

2.  HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects.

Authors:  Jingjing Yang; Lili Lin; Qihe Long; Qian Zhang; Guilan Sun; Liang Zhou; Qingyu Wang; Jun Zhu; Fanfan Li; Wei Hu
Journal:  BioDrugs       Date:  2022-05-20       Impact factor: 7.744

3.  Pan-Immune-Inflammation Value: A New Prognostic Index in Operative Breast Cancer.

Authors:  Fei Lin; Li-Ping Zhang; Shuang-Yan Xie; Han-Ying Huang; Xiao-Yu Chen; Tong-Chao Jiang; Ling Guo; Huan-Xin Lin
Journal:  Front Oncol       Date:  2022-04-13       Impact factor: 5.738

4.  The Effect of 1,2,4-Triazole-3-thiol Derivatives Bearing Hydrazone Moiety on Cancer Cell Migration and Growth of Melanoma, Breast, and Pancreatic Cancer Spheroids.

Authors:  Aida Šermukšnytė; Kristina Kantminienė; Ilona Jonuškienė; Ingrida Tumosienė; Vilma Petrikaitė
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-20

5.  COL11A1 serves as a biomarker for poor prognosis and correlates with immune infiltration in breast cancer.

Authors:  Qi Luo; Jinsui Li; Xiaohan Su; Qiao Tan; Fangfang Zhou; Shaoli Xie
Journal:  Front Genet       Date:  2022-09-09       Impact factor: 4.772

6.  Mammographic and Ultrasonographic Imaging Analysis for Neoadjuvant Chemotherapy Evaluation: Volume Reduction Indexes That Correlate With Pathological Complete Response.

Authors:  Juliana M Mello; Flavia Sarvacinski; Flavia C Schaefer; Daniel S Ercolani; Nathalia R Lobato; Yasmine C Martins; Guilherme Zwetsch; Fernando P Bittelbrunn; Charles F Ferreira; Andrea P Damin
Journal:  Cureus       Date:  2022-10-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.